Who is sponsoring NCT03243266?

NCT03243266 is sponsored by Beckman Coulter, Inc..

What drugs are being tested in NCT03243266?

Interventions in NCT03243266: CBC/Diff Reference Interval.

What condition does NCT03243266 study?

NCT03243266 studies Healthy Subjects.

Is NCT03243266 still recruiting?

NCT03243266 is currently completed. Last updated 13 July 2018.

Last reviewed 2018-07-13 · How we verify

NCT03243266

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

DxH520 Pediatric Reference Interval Verification

Completed Last updated 13 July 2018

What this trial tests

trial testing CBC/Diff Reference Interval in Healthy Subjects in 290 participants. Completed in 2 May 2018.

Timeline

19 June 2017

Primary endpoint
2 May 2018

2 May 2018

Quick facts

Lead sponsor	Beckman Coulter, Inc.
Status	Completed
Study type	OBSERVATIONAL
Enrollment	290
Start date	19 June 2017
Primary completion	2 May 2018
Estimated completion	2 May 2018
Sites	2 locations across Canada

Drugs / interventions tested

CBC/Diff Reference Interval

Conditions studied

Healthy Subjects — all drugs for Healthy Subjects →

Sponsor

Beckman Coulter, Inc.

Who can join

Adults 1 Minute to 21, any sex, with Healthy Subjects. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Results from this study will be used to verify that the published pediatric reference intervals are met on the DxH 520 Hematology Analyzer for the pediatric age ranges.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Healthy Subjects

Currently open trials in the same condition.

NCT07222020 — Phase 1 Study of Intravaginal KB15A · Phase 1 · recruiting
NCT07350538 — The Critical Link Between Gut Microbiome Dysfunction, Cravings and Relapse: RECLAIM-GUT TRIAL · NA · active not recruiting
NCT07304791 — This is a Phase 1, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Pharmacokinetics (PK), and P · Phase 1 · recruiting
NCT07059858 — Bladder and Bowel Functions, Participation and Quality of Life in Children With Intellectual Disabilities · recruiting
NCT07331389 — A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin · Phase 1 · recruiting

Other Beckman Coulter, Inc. trials

Trials by the same sponsor.

NCT07217431 — Access BNP Clinical Performance Evaluation: Testing and Clinical Concordance Study · completed
NCT06624293 — Access BNP Clinical Enrollment Study · completed
NCT06379061 — Access MeMed BV Assay Clinical Study Collection Protocol - Infectious Adult and Pediatric Cohorts · completed
NCT06289868 — Access Anti-HAV and Access Anti-HAV IgM Assays EU Clinical Trial Protocol (HAV-EU-11-23) · completed
NCT06257628 — MACE CDS Software Master Enrollment Protocol · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03243266 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Beckman Coulter, Inc.
Last refreshed: 13 July 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03243266.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing